BioHelix announced today that it has entered into a multi-year Cooperative Agreement with the National Institute of Allergy and Infectious Diseases (NIAID) to develop a simple and cost-effective IsoAmp® Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) test for use at STD clinics. In addition, after the successful completion of a Phase 1 Small Business Innovative Research (SBIR) HIV grant, the company has also received a three-year, Phase II Advanced Technology SBIR award from the NIAID for the development of a low-cost HIV molecular diagnostic test based on BioHelix's "instrument-free" IsoAmp® platform.